ArticleEpilepsy & behavior reports2025
Rash and edema shortly after initial exposure to low dose cenobamate.
Article in Epilepsy & behavior reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Impact of cenobamate on cortical responses to transcranial magnetic stimulation in people with drug-resistant focal epilepsy.Epilepsia open · 2026Article
- Cutaneous adverse reactions to low doses of cenobamate: don't DRESS it up…tell the truth!Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cenobamate (CNB) is an antiseizure medication (ASM) approved for the treatment of focal epilepsy. Rash and edema are uncommon adverse effects of this medication. We report two patients with medically refractory epilepsy (MRE) who received CNB and developed chest and facial rash and edema after the initial dose of 12.5 mg/d that prompted discontinuation of the medication with ensuing resolution of the rash and edema. Rechallenging with CNB resulted in similar reactions. Our report aims at increasing awareness of these reactions to CNB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.